SLC5A2 and metabolic dysfunction-associated steatotic liver disease: Compared with metformin, glimepiride, and dipeptidyl peptidase-4 inhibitors, SGLT2 inhibitors are associated with lower liver enzyme levels [141], regardless of the co-existence of NAFLD.